August 29, 2012 — The US Food and Drug Administration (FDA) has granted orphan drug status to gevokizumab (Xoma 052, Xoma Corp), a monoclonal antibody that binds strongly to interleukin 1β (IL-1β), ...

An investigational Janus kinase 1 (JAK1) preferential inhibitor reduced the risk of treatment failure among patients with active noninfectious uveitis, the phase II randomized HUMBOLDT trial showed.

An estimated five to ten percent of blindness worldwide is due to the rare inflammatory eye disease uveitis. Intermediate uveitis is often associated with a chronic course of the disease and the need ...

Have you ever noticed unexplained floaters or a slight blurriness in your vision? While these symptoms might seem minor, they could signal a condition called intermediate uveitis—a form of eye ...

Please provide your email address to receive an email when new articles are posted on . A local approach for the treatment of unilateral or asymmetric uveitis and systemic therapy for bilateral ...

Please provide your email address to receive an email when new articles are posted on . Avoid a “kitchen sink” work-up, instead focusing on history, findings and imaging. Treatment options include ...